VTCN1 and chordoma: In the present study, we profiled 45 skull base chordoma clinical samples by immunohistochemistry for the expression of 6 potential cell surface cancer immunotherapy targets (PD-L1, B7-H3, B7-H4, VISTA, HER2 and HER3).